Adverse cutaneous reactions to antipsychotics

American Journal of Clinical Dermatology

Volumn 3, Issue 9, 2002, Pages 629-636

  Warnock, Julia K ^a   Morris, David W ^b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TULSA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM CHLORIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DIBENZOXAZEPINE DERIVATIVE; DIPHENYLBUTYLPIPERIDINE DERIVATIVE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; THIOXANTHENE DERIVATIVE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

ACNE; ALOPECIA; DIAGNOSTIC ACCURACY; DRUG EFFECT; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ERYTHEMA MULTIFORME; EXFOLIATIVE DERMATITIS; HUMAN; HYPERHIDROSIS; MORBIDITY; OUTPATIENT; PATIENT COMPLIANCE; PHOTOSENSITIVITY DISORDER; PIGMENT DISORDER; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; REVIEW; SEBORRHEIC DERMATITIS; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; URTICARIA; VASCULITIS;

ANTIPSYCHOTIC AGENTS; DRUG HYPERSENSITIVITY; HUMANS; SKIN DISEASES;

EID: 0036914061     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203090-00005     Document Type: Review

References (59)

1. Srebrnik A, Hes JP, Brenner S. Adverse cutaneous reactions to psychotropic drugs. Acta Derm Venereol 1991; 158: 3-12
2. Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Application. 2nd Ed. Cambridge: Cambridge University Press, 2000
3. Medical Economics. Physician's Desk Reference. 55th Ed. Montvale (NJ): Medical Economics, 2001
4. Medical Economics. Physician's Desk Reference. 48th Ed. Montvale (NJ): Medical Economics, 1994
5. Garnis-Jones S. Dermatologic side effects of psychopharmacologic agents. Dermatol Clin 1996; 14 (3): 503-8
6. Pavlidakey GP, Hashimoto K, Heller GL, et al. Chlorpromazine-induced lupus-like disease: Case report and review of the literature. J Am Acad Dermatol 1985; 13 (1): 109-15
7. MacMorran WS, Krahn LE. Adverse cutaneous reactions to psychotropic drugs. Psychosomatics 1997; 38 (5): 413-22
8. Gold MS, Sweeney DR. Perphenazine-induced systemic lupus erythematosus-like syndrome. J Nerv Ment Dis 1978; 166 (6): 442-5
9. McNevin S, MacKay M. Chlorprothixene-induced systemic lupus erythematosus. J Clin Psychopharmacol 1982; 2 (6): 411-2
10. Dubois EL, Tallman E, Wonka RA. Chlorpromazine-induced systemic lupus erythematosus: Case report and review of the literature. JAMA 1972; 221 (6): 595-6
11. Warnock JK, Knesevich JW. Adverse cutaneous reactions to antidepressants. Am J Psychiatry 1988; 145: 425-30
12. Scuderi S, Gift TE. Thiothixene induced edema. Psychiatr Med 1986; 4 (3): 249-52
13. Hamann GL. Egan TM. Wells BG. et al. Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. J Clin Psychiatry 1990; 51 (12): 502-4
14. Welsh AL, Ede M. The fixed drug eruption. Arch Dermatol 1961; 84: 1012
15. Reilly GD, Wood ML. Prochlorperazine: An unusual cause of lip ulceration. Acta Derm Venereol 1984; 64 (3): 270-1
16. Matsuo I, Ozawa A, Niizuma K, et al. Lichenoid dermatitis due to chlorpromazine phototoxicity. Dermatologica 1979; 159 (1): 46-9
17. Eberlein-Konig B, Bindl A, Przybilla B. Phototoxic properties of neuroleptic drugs. Dermatology 1997; 194 (2): 131-5
18. Harth Y, Rapoport M. Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Drug Saf 1996; 14 (4): 252-9
19. Fitzpatrick TB, Johnson RA, Wolff K, et al. Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases. 4th Ed. New York: McGraw-Hill. 2001
20. Satanove A. Pigmentation due to phenothiazines in high and prolonged dosage. JAMA 1965; 191 (4): 263-8
21. Robins AH. Phenothiazine melanosis in schizophrenic patients. Psychopharmacologia 1972; 27 (4): 327-42
22. Forrest FM, Snow HL, Erickson G, et al. Incidence of late 'melanosis' side effects in chronic mental patients after long term phenothiazine therapy. Proc West Pharmacol Soc 1966; 9: 18-20
23. Gibbard BA, Lehmann HE. Therapy of phenothiazine-produced skin pigmentation: A preliminary report. Am J Psychiatry 1966; 123 (3): 351-2
24. Berger H. Pigmentation after thioridazine [letter]. Arch Dermatol 1969; 100 (4): 487
25. Buckley C, Thomas V, Lewin J, et al. Stelazine-induced pigmentation. Clin Exp Dermatol 1994; 19 (2): 149-51
26. Lal S, Bloom D, Silver B, et al. Replacement of chlorpromazine with other neuroleptics: Effect on abnormal skin pigmentation and ocular changes. J Psychiatry Neurosci 1993; 18 (4): 173-7
27. Bloom D, Krishnan B, Thavundayil JX, et al. Resolution of chlorpromazine-induced cutaneous pigmentation following substitution with levomepromazine or other neuroleptics. Acta Psychiatr Scand 1993; 87 (3): 223-4
28. Thompson TR, Lal S, Yassa R, et al. Resolution of chlorpromazine-induced pigmentation with haloperidol substitution. Acta Psychiatr Scand 1988; 78 (6): 763-5
29. Ewing DG, Einarson TR. Loxapine as an alternative to phenothiazines in a case of oculocutaneous skin pigmentation. Am J Psychiatry 1981; 138 (12): 1631-2
30. Lal S, Lal S. Chlorpromazine-induced cutaneous pigmentation: Effect of replacement with clozapine [letter]. J Psychiatry Neurosci 2000; 25 (3): 281
31. Lautenschlager S, Itin PH. Reticulate, patchy and mottled pigmentation of the neck: Acquired forms. Dermatology 1998; 197 (3): 291-6
32. Benning TL, McCormack KM, Ingrain P, et al. Microprobe analysis of chlorpromazine pigmentation. Arch Dermatol 1988; 124 (10): 1541-4
33. Rohrborn W, Brauninger W. Thioridazine photoallergy [letter]. Contact Dermatitis 1987; 17 (4): 241
34. Suhonen R. Thioridazine photosensitivity [letter]. Contact Dermatitis 1976; 2 (3): 179
35. Satanove A, McIntosh JS. Phototoxic reactions induced by high doses of chlorpromazine and thioridazine. JAMA 1967; 200 (3): 209-12
36. Torinuki W. Contact dermatitis to biperiden and photocontact dermatitis to phenothiazines in a pharmacist. Tohoku J Exp Med 1995; 176 (4): 249-52
37. Harth Y, Rapport M. Phototoxicity associated with antipsychotics, antidepressants, and anxiolytics. Drug Saf 1996; 14: 252-9
38. Epstein JH, Wintroub BU. Photosensitivity due to drugs. Drugs 1985; 30 (1): 42-57
39. Ban TA, Guy W, Wilson WH. Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients. Can J Psychiatry 1985; 30 (6): 406-8
40. Satanove A. Pigmentation due to phenothiazines in high and prolonged dosage. JAMA 1965; 191: 263-8
41. Zelickson AS. Skin pigmentation and chlorpromazine. JAMA 1965; 194 (6): 670-2
42. Greiner AC, Berry K. Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy. Can Med Assoc J 1964; 90: 663-4
43. Chignell CF, Motten AG, Buettner GR. Photoinduced free radicals from chlorpromazine and related phenothiazines: Relationship to phenothiazine-induced photosensitization. Environ Health Perspect 1985; 64: 103-10
44. King DL. Neuroleptics and the treatment of schizophrenia. In: King DL, editor, for the Royal College of Psychiatrists. Seminars in Clinical Psychopharmacology. London: Gaskell, 1995
45. Ban TA, Guy W, Wilson WH. Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients. Can J Psychiatry 1985; 30: 406-8
46. Bond WS, Yee GC. Occular and cutaneous effects of chronic phenothiazine therapy. Am J Hosp Pharm 1980; 37: 74-8
47. Wolf ME, Richer S, Berk MA, et al. Cutaneous and ocular changes associated with the use of chlorpromazine. Int J Clin Pharmacol Ther Toxicol 1993; 31: 365-7
48. Kimyai-Asadi A, Harris JC, Nousari HC. Critical overview: Adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999; 60 (10): 714-25
49. Thompson TR, Lai S, Yassa R, et al. Resolution of chlorpromazine-induced pigmentation with haloperidol substitution. Acta Psychiatr Scand 1988; 78: 763-5
50. Mercke Y, Sheng H, Khan T, et al. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000; 12 (1): 35-42
51. Kubota T, Ishikura T, Jibiki I. Alopecia areata associated with haloperidol. Jpn J Psychiatry Neurol 1994; 48: 579-81
52. Warnock JK. Psychotropic medication and drug-related alopecia. Psychosomatics 1991; 32 (2): 149-52
53. Blankenship ML. Drugs and alopecia. Australas J Dermatol 1983; 24: 100-4
54. Simpson GH, Pi EH, Sramek JJ. Neuroleptics and anti-psychotics. In: Dukes MNG, editor. Meyer's Side Effects of drugs. Amsterdam: Elsevier, 1982: 95-108
55. Raz A, Bergman R, Eilam O, et al. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 2001: 321 (2): 156-8
56. Flint A. The skin in Parkinson's disease. Prim Care 1977; 4: 475-80
57. Binder RI, Jonelis FJ. Seborrheic dermatitis: A newly reported side effect of neuroleptics. J Clin Psychiatry 1984; 45: 125-6
58. Binder RI, Jonelis FJ. Seborrheic dermatitis in neuroleptic-induced parkinsonism. Arch Dermatol 1983; 119: 473-5
59. Daoud MS, Schanbacher CF, Dicken CH. Recognizing cutaneous drug eruptions: Reaction patterns provide clues to causes. Postgrad Med 1998; 104: 101-15